Management of Stress Urinary Incontinence in Patients with Underactive Bladder.

Eur Urol Focus

Urology Department, La Fe University and Polytechnic Hospital, Valencia, Spain. Electronic address:

Published: May 2025


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

The coexistence of detrusor underactivity (DUA) and female stress urinary incontinence presents a challenge for urologists. The various DUA definitions used in the literature and the predominantly retrospective nature of most studies contribute to a low level of evidence regarding optimal management for these patients. However, efficacy outcomes appear to be quite similar to those observed for patients without DUA, albeit with a slight increase in voiding symptoms. The role of adjustable slings, bulking agents, and artificial urinary sphincters remains unclear, so identification of the most appropriate solution via a shared decision-making process with the patient is essential. PATIENT SUMMARY: For women who have stress urinary incontinence, management can be difficult for those who also have an underactive bladder. This mini review discusses the treatment options available and their advantages and disadvantages. Shared decision-making between the doctor and patient is crucial in choosing the option that best suits an individual patient's needs.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.euf.2025.04.030DOI Listing

Publication Analysis

Top Keywords

stress urinary
12
urinary incontinence
12
underactive bladder
8
shared decision-making
8
management stress
4
urinary
4
incontinence patients
4
patients underactive
4
bladder coexistence
4
coexistence detrusor
4

Similar Publications

The stress urinary incontinence (SUI) is a difficulty in urology and current sub-urethral sling treatments are associated with inflamation and recurrence. In this study, we developed a novel tissue-engineered sling with myogenic induced adiposederived stem cells (MI-ADSCs) sheets induced by 5-Aza and combined with electrospun scaffolds of silk fibroin and poly(lactide-co-glycolide) (SF/PLGA) for the treatment of stress urinary incontinence. MI-ADSCs increased α-SMA, MyoD and Desmin the mRNA and protein expression.

View Article and Find Full Text PDF

Sodium-glucose Cotransporter 2 (SGLT-2) inhibitors are oral antidiabetic drugs that were developed for the treatment of patients with diabetes mellitus and are now also approved for treating chronic heart failure and chronic kidney disease. By inhibiting SGLT‑2 in the proximal renal tubule, urinary excretion of glucose is increased. Large randomized trials have demonstrated improved glycemic control, reduced cardiovascular events and lower mortality but also an increased risk of urogenital infections and dehydration.

View Article and Find Full Text PDF

Diabetic nephropathy (DN) is a major cause of end-stage renal disease, with podocyte injury representing an early pathogenic event. Conventional biomarkers such as albuminuria and eGFR identify renal damage only at advanced stages, limiting opportunities for timely intervention. Wilms' Tumor 1 (WT1), a podocyte-specific transcription factor, has emerged as a sensitive marker of early glomerular stress.

View Article and Find Full Text PDF

Diabetic nephropathy (DN) is a major complication of diabetes, imposing substantial socioeconomic and public health challenges. N6-methyladenosine (m6A) modification, a prevalent epigenetic mechanism, influences cellular processes and disease progression. Wilms' tumor 1-associating protein (WTAP), an m6A methyltransferase subunit, was investigated for its role in DN.

View Article and Find Full Text PDF

Circular RNA (circRNA) has been confirmed to be a regulator for septic acute kidney injury (AKI). It is reported that circ_0049271 has abnormal expression in AKI patients, but its role and mechanism in septic AKI remain unclear. Lipopolysaccharide (LPS)-stimulated HK-2 cells were served as the cellular model of sepsis-associated AKI (SAKI).

View Article and Find Full Text PDF